Covid Vaccine Race

Vaccine manufacturer Valneva recently announced it was initiating a phase 1/2 trial in the United Kingdom.

The agreement could mean upwards of 70 million more doses for eligible patients in mid-2021.

Though research is pending, the CEO used simple science to explain why the mRNA vaccine may still prevent from the UK variant.

The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.

At the interim analysis, the mRNA-1273 vaccine was found to have an efficacy of 94.5% against confirmed COVID-19.

Up to 40% more doses—or, enough to vaccinate another person with two doses—has been observed in the vials distributed at the beginning of this week.

Covaxx CEO Mei Mei Hu has seen vaccines from development all the way through to government approval. She offers her unique perspective into vaccine creation and an update on her company’s COVID-19 vaccine.

Data from three ongoing clinical studies were included in the EUA request.

The country's first authorized vaccine will be first available to healthcare workers and long-term care residents.

The VRBPAC committee voted 17-4, with 1 abstention, to support the benefit-risk profile of BNT162b2 for preventing COVID-19 in persons aged 16 years and older.

Pending investigations of 2 severe adverse events, people with a history of severe allergies are being advised by the UK’s regulatory agency not to get vaccinated.

Just one day before the FDA meeting to discuss potential US authorization of the Pfizer and BioNtech vaccine, that country approves the vaccine.

The first COVID-19 vaccines in the US will be from the unique platform. An expert explains how they work.

The announcement follows Pfizer and Moderna who both showed their vaccines to be over 90% efficacious.

Public understanding of adverse events could be an obstacle in the rollout of vaccines to fight the coronavirus disease 2019 (COVID-19).

The primary outcome was to determine how many cases of symptomatic COVID-19 disease there were in participants who had received two doses of the vaccine.

The updated vaccine efficacy and safety outcomes include 37,000-plus participants from the ongoing, multi-national trial.

The study was posted to the website clinicaltrials.gov this past Wednesday.

Authorization for a COVID-19 vaccine in the US appears imminent, bringing with it a host of concerns including the speed of development, inclusivity of clinical trials, safety of mRNA technology, and how to raise levels of trust in vulnerable populations.

Tonix Pharmaceuticals is developing a horsepox virus vector vaccine based on a historic platform which was first used for smallpox, and applying it to the world’s most recent virus.

While the antibodies declined slightly at 3 months, all participants showed elevated levels.

Initial high hopes for third vaccine available to the public, in addition to Pfizer and Moderna’s versions, are tempered as further data is sought.

The Advisory Committee on Immunization Practices (ACIP) met yesterday and decided that healthcare workers and residents in long-term care facilities will be prioritized as the first people eligible for the impending COVID-19 vaccines.

The companies are ready to ship doses immediately.

Here is everything you need to know about the second vaccine submitted for an EUA this year.

A look at the logistical questions which remain with the two leading candidates.

The former FDA commissioner weighs in on the best measures to mitigate skyrocketed new cases, and his timeline for national recovery.

OncoSec recently received an FDA IND clearance to begin a phase 1 trial.

This CDC panel discussed who should be vaccinated first and the flu-like effects from the vaccines.

Data shows their AZD1222 vaccine met its endpoint and they are preparing regulatory submission for conditional or early approval.